Skip to content

**NEW INDICATION: BRAFTOVI® (encorafenib) 75-mg capsules from Pfizer Inc.

4/20/2020

Pfizer Inc. is pleased to announce that the US Food and Drug Administration has approved BRAFTOVI®

(encorafenib) for a new indication. The following information is for State Society review:

Approval information: https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_braftovi_encorafenib_in_combination_with_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer_crc_after_prior_therapy

Prescribing Information: http://labeling.pfizer.com/ShowLabeling.aspx?id=12990

Procurement information

BRAFTOVI 75-mg capsules:

• 120 capsules: NDC # 70255-025-03

For information about ordering and dispensing BRAFTOVI, please call 1-844-492-7729.


I expect to be fully trained on BRAFTOVI + cetuximab on May 1, 2020, if you have any questions before that

time, please refer to Pfizer Medical Information at 1-800-438-1985 or www.pfizermedicalinformation.com


© 2020 Pfizer Inc. All right reserved. BRAFTOVI® is a registered trademark of Array BioPharma Inc. in the United

States and various other countries. NP-US-BC-0026 v1

Powered By GrowthZone